MedPath

Novo Nordisk A/S

Novo Nordisk A/S logo
🇩🇰Denmark
Ownership
Public
Established
1923-01-01
Employees
63.3K
Market Cap
$602.2B
Website
http://www.novonordisk.com
bioworld.com
·

Novo's injectable hemophilia treatment approved by FDA

Subscribe to BioWorld™ news services.
media.market.us
·

AI in Medicine Market Expected To Grow At 27.6% CAGR By 2033

AI in Medicine Market to reach USD 156.8B by 2033, growing at 27.6% CAGR. Driven by AI tech advancements, personalized medicine, and chronic disease management, with North America leading in 2023. AI enhances diagnostics, treatment, and healthcare efficiency.
bnnbloomberg.ca
·

Novo Nordisk Falls Most on Record After New Weight Drug Disappoints

Novo Nordisk's CagriSema obesity shot showed 20.4% weight loss over 68 weeks, falling short of the 25% target. The results align with Eli Lilly's Zepbound, with Lilly's retatrutide showing up to 24% weight loss. Novo's shares dropped 27%, erasing $120 billion in market value, while Lilly's shares rose 10%. Novo plans to start a new trial in H1 2024 to optimize doses and expects regulatory approval by year-end 2024. The study suggests side effects may have limited patient adherence, with 22.7% weight loss in patients who stayed on treatment.
aspconline.org
·

Novo Nordisk A/S: CagriSema demonstrates superior ...

ASPC introduces a new website and membership portal, urging members to login to update accounts. Transitioning to a calendar year renewal system by end of 2024, with dues prorated for 2024. Questions can be emailed to contact@aspconline.org.
quantisnow.com
·

Catalent and Novo Holdings Fulfill All Regulatory Closing Conditions for Pending Transaction

Catalent, Inc. and Novo Holdings A/S have fulfilled all regulatory closing conditions for their pending transaction, expected to close in the coming days. Catalent's CEO, Alessandro Maselli, expressed excitement for the company's future under Novo Holdings' ownership, emphasizing innovation and enhanced offerings. Jonathan Levy, Senior Partner at Novo Holdings, highlighted the benefits of the transaction for driving healthcare innovation and improving patient outcomes.
bnnbloomberg.ca
·

Eli Lilly's Mounjaro Won't Have Separate Sleep Apnea Label in EU

Eli Lilly's Mounjaro won't be reclassified as a sleep apnea treatment in Europe; its use for weight loss remains unchanged. The European Medicines Agency will include sleep apnea data in Mounjaro's product information. Lilly and Novo Nordisk compete for dominance in the obesity drug market, estimated to reach $130 billion by 2030. Mounjaro, branded as Zepbound in the US and Mounjaro in Europe, is also under FDA review for sleep apnea.
bloomberg.com
·

Ozempic, Wegovy, Zepbound Due for Competition From New Obesity Drugs

Novo Nordisk and Eli Lilly dominate the obesity-treatment market with drugs like Ozempic, Wegovy, Zepbound, and Mounjaro. By 2025, results from numerous midstage trials will challenge this duopoly, aiming for less frequent dosing, greater weight loss, and fewer side effects.
media.market.us
·

Clinical Trials Market To Surpass US$ 886 Billion By 2032

The Clinical Trials Market is projected to grow from US$483B in 2023 to US$886.5B by 2032, driven by personalized medicine, tech advancements, and chronic disease prevalence. North America leads, while Asia-Pacific grows rapidly. Key trends include AI, decentralized trials, and regulatory support for inclusivity and efficiency.
einpresswire.com
·

Revolutionizing the Oral Proteins And Peptides Market in 2024

The oral proteins and peptides market is projected to grow to $2.86 billion by 2028 at a CAGR of 22.4%, driven by factors like rising chronic diseases, biotechnology investments, and non-invasive treatments. Key advancements include novel oral peptides, AI in drug discovery, and oral insulin formulations.
menafn.com
·

Revolutionizing The Oral Proteins And Peptides Market In 2024: Breakthrough Oral Insulin Technologies In Diabetes Care

The oral proteins and peptides market is projected to grow from $1.04 billion in 2023 to $2.86 billion by 2028, with a CAGR of 22.4%. Growth drivers include chronic diseases, biotech investments, non-invasive treatments, and personalized medicine. Innovations like AI in drug discovery and oral insulin formulations are key trends. North America leads, with Asia-Pacific expected to grow fastest.
© Copyright 2025. All Rights Reserved by MedPath